





# MODEL GENERATION TECHNICAL REPORT

RMCE cassette (FRT-pCAG-Flpe-HygroR-F3) into the Rosa26 locus

Project code: K500 / IR2365

Report finalized: 2024/12/03







de la santé el de la rerisorrise médicale





















## Project process & quality controls











Target locus structure



#### Location : Chromosome 6: 113,043,843-113,055,336

chromosome 6

### Gene: Gt(ROSA)26Sor ENSMUSG0000086429



## **B** HOMOLOGOUS RECOMBINATION - VECTOR CONSTRUCTION







- Electroporation and screening process
- Long range PCR screening strategy
- Long-Range 3' PCR screening results
- Recombinant ES validation by Long Range PCR
- Recombinant ES clones validation by Southern Blot internal probe
- Recombinant ES clones validation by Southern Blot External probe
- Aneuploidy screening in ES recombinant clones



The targeting vector was electroporated in the proprietary C57BL/6NTac (BD10) embryonic stem cell line.

Transfected ES clones were submitted to neomycin selection (G418) and 186 resistant ES clones were isolated. The clones were then submitted to the screening process allowing secured identification of those harbouring the expected recombination events at both ends of targeting vector.

Screening process steps:

- 1. Identification of candidate recombinant clones by initial 3' Long-Range PCR
- 2. Three of 3' PCR positive clones are confirmed for 3' recombination event by Long-Range PCR
- 3. Positive clones in step2 are further validated by Southern blot analysis using internal and external probes
- 4. The karyotype of at least 2 validated clones is verified using Giemsa staining





## Long range PCR screening – strategy

#### Schematic 5' and 3' PCR screening strategy



PCR	Primer Name	Primer sequences	PCR product size
2/ 000	Fhyg	CGCCGATAGTGGAAACCGACGCCC	4 7 1.1.
3" PCR	Rext	CTCAGTGGCTCAACAACACTTGGTC	4.7 KD
2' DCD	Fint	CTGGTGTGTGGGCGTTGTCCTGCAG	4.4.6
3 PCR	Rext CTCAGTGGCTCAA	CTCAGTGGCTCAACAACACTTGGTC	4.4 KD



### Long-Range 3' PCR screening – results





Wild type Allele (WT)



**Targeting Vector** 

Targeted Allele (HR)



**phen@min čš** EXCELLENCE IN MOUSE PHENOGENOMICS

Three candidate clones out of the positive clones were selected for 3' Long-Range PCR and Southern blot validation.

- 300 - 200 - 100

Ladder pattern

## Recombinant ES validation by Long Range PCR

#### **Confirmation and Validation of candidate recombinant ES clones by 5' and 3' PCRs**



Three candidate clones (clones #4, #90, and #185) identified by 3' PCR screening were further analysed by 3' Long-Range PCR and Southern blot.



## Recombinant ES clones validation by Southern Blot – Internal probe

**Schematic Southern Blot validation strategy** 

Digests on the scheme illustrate the position of the chosen restriction sites relative to the probe. They don't show the exact position of the restriction sites.





#### Hygro probe sequence

#### Digestions used to validate the 5' and 3' insertion

Probe		Genomic DNA digest	Targeted Allele (kb)
Hygro	5' digest	BstEll	9.9
		EcoNI	9
	3' digest	Xbal	7.8
		EcoRV	12.2



## Recombinant ES clones validation by Southern Blot – External probe





#### 5' probe sequence

#### Digestions used to validate the 5' and 3' insertion

Probe	Name	Genomic DNA digest	WT allele (kb)	Targeted Allele (kb)
5'	5' first digest	Avrll	5.2	10.5
external probe	5' second digest	Sspl	4.1	9.3



Selected recombinant ES cells clones were karyotyped by Giemsa metaphase staining. Results of aneuploidy analysis are presented in the table below.

Clone ID	Giemsa
#4	Pass
#90	Pass
#185	Failed







Microinjection

Breeding to F1 generation



- The ES cells used in the injection experiment were originally derived from a C57BL/6Tac (BD10) mouse strain (which have black coat colour). These cells were injected into blastocysts derived from an BALB/cN strain, which have a white coat colour. The resulting offspring are thus chimeras of two different cell types (ES cell-derived cells and host blastocyst-derived cells) and the degree of chimerism was monitored by the percentage of light and dark patches on these animals.
- Recipient blastocysts were isolated from mated BALB/cN females (Health status SPF Specific Pathogens Free).
- Recombinant ES clone #90 validated in previous project phase was injected into blastocysts to generate chimeric males. The results are presented in the table below.

	Number of chimeric males identified according to chimerism rate (Number of chimeric males bred to F1 generation)			
Clone ID	5 - 40%	45% - 55%	60-100%	Total
#90	1	0	10	11







Four highly chimeric males generated in the previous phase by blastocyst injection of the ES clone #90 were mated with wild-type C57BL/6NTac females (health status SPF – Specific Pathogen Free) to investigate whether the recombined ES cells have contributed to the germ layer.

Germ line transmission was obtained the : 26/08/2009

MGI allele ID: MGI:7788436

Allele nomenclature (following MGI guidelines) : **Gt(ROSA)26Sor**<sup>tm16(CAG-flpe)Ics</sup>



## **6** SEQUENCE OF THE DELIVERED ALLELE



CAGGCTTAAAGGCTAACCTGGTGTGGGGCGTTGTGGGGCGCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCG TAGAGCCTCTGCTAACCATGTTCATGCCTTCTTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATCTTGGCAAAGAATTCTGAGCCGCCACCATGAGCCCACCATGTATATTATGTAAAACACCACCTAAGGTCCTGGTTCGTCAGCTGGCAAAGGTTTGAAAGACCC TTCAGGGGAAAAAATAGCATCATGTGCTGCTGCTGAACTAACCTATTATGTTGGATGATTACTCATAAGGAACAGCAATTCATGAGGGAAAAAGCAACTATCATAAGCAATCATCATGAGCAATTCGCTGCTGAACTAACCAAGACGACTACTATGAGACGAACAACAATTC CTTAGTCAGATCGTACAACAAGGCTTTGAAGAAAAATGCGCCCTATCCAATCTTTGCTATAAAGAATGGCCCCAAAATCTCCACATTGGAAGACATTTGATGACCTCATTGCTAGTGAGGGCCTAACGGAGCTTGACGAAAATGCGCGCCTAACGGAGCGATAAGCGTGCCCACAGACTCGCAGGAGCCACAGGCCTAACGGAGCCTAACGGAGCGAAAATGCCCCAAAATCTCCACATTGGAAGACATTTGGAAGACATTTGGAGGGCCTAACGGAGCCTAACGGAGCCTAACGGAGCGATAAGCGTGCCCAAAATCTCCACATTGGAAGACATTTGGAAGACATTTGGAAGGGCCTAACGGAGCCTAACGGAGCTTGACGAGCGAAAATGCCCCAAAATCTCCACATTGGAAGACATTTGGAAGACGTGCCCAAAATCTCACATTGGAAGACATTTGGAAGGGCCTAACGGAGCTTGACGGAGAAATGGCGCGTGCCCAGAATCTCGCCGGGAAATCTCCACATTGGAAGACATTGGAAGACATTTGATGACCTCATTGGAAGGGCCTAACGGAGCTTGACGAAGCGTGCCTAACGGAGCGTGCCCAAAATCTCCACATTGGAAGACATTTGGAAGACGTGCCCAAAATCTCACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACATTTGGAAGACATTGGAAGACGTGCCCAAAATCTCACATTGGAAGACATTGGAAGACATTGGAAGACATTGGAAGACATTGGAAGACATTGGAAGGGCCTAACGGAGCGTGACTAATGTGGAAGACATTGGAAGACATTGGAAGACATTGGAAGACATTGGAAGCGTGCCAAAATGTCCAATGTGAGAAGACATTGGAAGACAT GGGGTGGGGGTGGGGTGGGATTAGATAAATGCCTGCTCTTTACTGAAGGCTCTTTACTATTGCTTTACTATTGGATAATGTTTCATAGTTGGATGAAGAATAGGAACTTCCATCAGGCGGGAATTGCAAGGGGGAATTGAACAGGTGTAAAATTGGAGGGACAAGACTTCCCACAGATTT CAGTATGAAATTACAGTGTCGCGAGTTAGACTATGTAAGCAGAATTTTAATCATTTTTAAAGAGCCCAGTACTTCATATCCATTTCCCCGCTCCTTCTGCAGCCTTATCAAAAGGTATTTTAGAACACTCATTTTAGACCCCATTTTCATTATACTGGCTTATCCAAACCCCTAGACAGAGCATT 

FRT

Flpe

PCAG

Beta globin pA

HygroR



phen@min cs

EXCELLENCE IN MOUSE PHENOGENOMICS







#### **REPORT REDACTION & VALIDATION**

Protocol finalized on 2024/12/03 Prepared by Romain LORENTZ, IE Verified by Marie-Christine BIRLING, PhD

**CONTACT US** By email at <u>mutagenesis@igbmc.fr</u> By phone at +33 (0)3 88 65 57 43

## www.phenomin.fr







de la santé et de la recherche médicale









This report has been prepared by:

Christelle Roth genotyping@igbmc.fr

This report has been validated by:

**Sylvie Jacquot, PhD, Head of Genotyping Service** 33 (0)3 88 65 57 44 genotyping @igbmc.fr

The first version of this report was generated the: 07 Aug 2014

For any question, please contact:

Institut Clinique de la Souris - ICS - Mouse Clinical Institute 1 rue Laurent Fries, BP 10142 67404 Illkirch Cedex, France Email: <u>mutagenesis@igbmc.fr</u> Web site: <u>http://www-mci.u-strasbg.fr/</u>



1 rue Laurent Fries - 67404 Illkirch Cedex - France - T. 33 (0)3 88 65 56 57 - F. 33 (0)3 88 65 56 90



#### TABLE OF CONTENTS

Tabl	le of d	contents	2
1.	Gend	otyping protocol and data	2
1	.1.	Genotyping strategy	2
1	.2.	PCR protocol	4
_		· •· • •	•

#### 1. Genotyping protocol and data

This section describes the condition used at the Mouse Clinical Institute (ICS) to genotype your **FRT-F3 RMCE cassette Rosa** Knockin (KI) project.

#### **1.1. Genotyping strategy**

The map below describes the position of the primers used for genotyping for each possible allele.



#### RMCE cassette in Rosa26



	Sequence of primers used for genotyping:
Position	Sequence
Wf	TAAGGGAGCTGCAGTGGAGTAGGCG
Wr	TAGTAAGGATCTCAAGCAGGAGAG
KIF	CCTTATTCCAAGCGGCTTCGGC
KIR	TCCATATATGGGCTATGAACTAATG

	PCR fr	agments expe	ected size (bp)
Region analyzed	Position on	Targeted	WildType
	the primer	allele (HR)	allele
	(see the		
	map above)		
WildType allele specific	Xf / Wr	5684*	484
PCR_5' KI	Xf / KIR	353	
PCR_3' KI	KIF / Wr	447	

\*: this PCR product will not be observed using our PCR genotyping conditions (see description below) ---: no Amplicon should be obtained

#### institut Clinique de la Souris



#### 1.2. PCR protocol

This section describes the composition of the mix and cycling conditions used for genotyping.

Reagents:	Volume:
- FastStart PCR Master (Roche)	7.5µl
- DNA (50ng/μl)	1.5µl
- 5' primer (100 μM)	0.06µl
- 3' primer (100 μM)	0.06µl
- Sterile H <sub>2</sub> O	up to 15 μl

Cycling conditions:				
Temp	Time	#Cycles		
95°C	4min	1		
94°C	30s			
62°C	30s	34		
72°C	1min			
72°C	7min	1		
20°C	5min	1		

NB: These PCR conditions have been optimized for high-throughput genotyping. Adaptation to small-scale may be required.



#### 2. Cre and Flp genotyping method

You will find the genotyping protocol in the publication:

Highly-efficient, fluorescent, locus directed cre and FlpO deleter mice on a pure C57BL/6N genetic background.

Birling MC, Dierich A, Jacquot S, Hérault Y, Pavlovic G. Genesis. 2012 Jun;50(6):482-9. doi: 10.1002/dvg.20826. Epub 2012 Mar 20.